Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to PET ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Neuroendocrine neoplasms: dichotomy, origin and classifications.Visc Med. 2017; 33: 324
- Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management.World J Gastroenterol. 2020; 26 (Available at:): 2305-2322
- Synaptophysin: a marker protein for neuroendocrine cells and neoplasms.Proc Natl Acad Sci U S A. 1986; 83: 3500-3504
- Nothing but NET: a review of neuroendocrine tumors and carcinomas.Neoplasia (United States). 2017; 19: 991-1002
- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2020; 31: 844-860
- Gastroenteropancreatic neuroendocrine tumors.CA Cancer J Clin. 2018; 689: 471-487
- Lung neuroendocrine neoplasms: recent progress and persistent challenges.Mod Pathol. 2022; 35: 36
- Emerging therapeutic concepts and latest diagnostic advancements regarding neuroendocrine tumors of the gynecologic tract.Medicina (Kaunas). 2021; 57
- Neuroendocrine tumors of the breast.Arch Pathol Lab Med. 2017; 141: 1577-1581
- Consensus guidelines for the management and treatment of neuroendocrine tumors.Pancreas. 2013; 42: 557
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.J Clin Oncol. 2009; 27: 4656-4663
- Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: recent insights.Onco Targets Ther. 2020; 13: 3545
- Activity and safety of standard and prolonged capecitabine/temozolomide administration in patients with advanced neuroendocrine neoplasms.Neuroendocrinology. 2019; https://doi.org/10.1159/000500135
- Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: a meta-analysis.Medicine (Baltimore). 2018; 97https://doi.org/10.1097/MD.0000000000012784
- Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.J Clin Oncol. 2004; 22: 4710-4719
- FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide–platinum combination in patients with neuroendocrine carcinomas grade 3.Endocr Relat Cancer. 2012; 19: 751-757
- Incidence of neuroendocrine tumors in the United States from 2001-2015: a United States cancer statistics analysis of 50 states.Cureus. 2019; 11https://doi.org/10.7759/CUREUS.4322
- Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.JAMA Oncol. 2017; 3: 1335
- Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms.Endocrine. 2017; 58: 368
- Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?.Curr Oncol Rep. 2021; 23https://doi.org/10.1007/S11912-021-01029-7
- Update on epidemiology, diagnosis, and biomarkers in gastroenteropancreatic neuroendocrine neoplasms.Cancers (Basel). 2022; 14: 1119
- Racial differences in the incidence and survival of patients with neuroendocrine tumors.Pancreas. 2019; 48: 1373-1379
- Racial differences in gastroenteropancreatic neuroendocrine tumor treatment and survival in the United States.Pancreas. 2021; 50: 29-36
- Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study.Cancer Med. 2017; 6: 2745-2756
- Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases.Cancer. 2018; 124: 807-815
- Siegfried Oberndorfer: origins and perspectives of carcinoid tumors.Hum Pathol. 2004; 35: 1440-1451
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.Virchows Arch. 2006; 449: 395-401
- The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5.Exp Ther Med. 2021; 22https://doi.org/10.3892/ETM.2021.10613
- What is new in the 2019 World Health Organization (who) classification of tumors of the digestive system: review of selected updates on neuroendocrine neoplasms, appendiceal tumors, and molecular testing.Arch Pathol Lab Med. 2021; 145: 664-677
- Classification of neuroendocrine neoplasms: lights and shadows.Rev Endocr Metab Disord. 2021; 22: 527-538
- Molecular classification of neuroendocrine tumors of the thymus.J Thorac Oncol. 2019; 14: 1472-1483
- ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine and hybrid imaging.Neuroendocrinology. 2017; 105: 212-244
- Guidelines detail.(Available at:) (Accessed April 18, 2022)
- Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.Endocr Relat Cancer. 2018; 25: R11-R29
- Chromogranin A: any relevance in neuroendocrine tumors?.Curr Opin Endocrinol Diabetes Obes. 2016; 23: 28-37
- An assessment of circulating chromogranin a as a biomarker of bronchopulmonary neuroendocrine neoplasia: a systematic review and meta-analysis.Neuroendocrinology. 2020; 110: 198-216
- The NETest: the clinical utility of multigene blood analysis in the diagnosis and management of neuroendocrine tumors.Endocrinol Metab Clin North Am. 2018; 47: 485-504
- Assessment of NETest clinical utility in a U.S. Registry-Based Study.Oncologist. 2019; 24: 783-790
- NETest: a systematic review focusing on the prognostic and predictive role.Neuroendocrinology. 2021; (Published online August 5)https://doi.org/10.1159/000518873
- Work up of gastroenteropancreatic neuroendocrine tumors.Surg Oncol Clin N Am. 2020; 29: 165
- Gastric neuroendocrine neoplasms: a review.World J Clin Cases. 2021; 9: 7973
- Increased grade in neuroendocrine tumor metastases negatively impacts survival.Ann Surg Oncol. 2017; 24: 2206-2212
- Neuroendocrine tumor diagnosis and management: 68 Ga-DOTATATE PET/CT.AJR Am J Roentgenol. 2018; 211: 267-277
- A delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management.Endocr Connect. 2016; 5: 174
- Whole-body 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.J Clin Endocrinol Metab. 2005; 90: 3392-3400
- 68Ga PET imaging in patients with neuroendocrine tumors: a systematic review and meta-analysis.Clin Nucl Med. 2018; 43: 802-810
- Morphological and functional imaging for detecting and assessing the resectability of neuroendocrine liver metastases.Neuroendocrinology. 2018; 106: 74-88
- The value of 68Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared with current FDA approved imaging modalities: a review of literature.Am J Nucl Med Mol Imaging. 2014; 4: 426
- Role of [68Ga]DOTANOC PET/computed tomography and [131I]MIBG scintigraphy in the management of patients with pheochromocytoma and paraganglioma: a prospective study.Nucl Med Commun. 2020; 41: 1047-1059
- The utility of 68 Ga-DOTATATE PET/CT in localizing primary/metastatic pheochromocytoma and paraganglioma in children and adolescents - a single-center experience.J Pediatr Endocrinol Metab. 2020; 34: 109-119
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors.N Engl J Med. 2014; 371: 224-233
- Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors.N Engl J Med. 2017; 376: 125-135
- Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.Ann Oncol. 2017; 28: 1569
- Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol. 2017; 18: 1411-1422
- Surgical management of neuroendocrine tumours of the pancreas.J Clin Med. 2020; 9: 1-18
- Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.N Engl J Med. 2011; 364: 501-513
- Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, Phase III RADIANT-3 study.J Clin Oncol. 2016; 34: 3906-3913
- Everolimus for advanced pancreatic neuroendocrine tumors.N Engl J Med. 2011; 364: 514-523
- Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience.Cancer Chemother Pharmacol. 2013; 71: 663-670
- The role of conventionally fractionated radiotherapy and stereotactic radiotherapy in the treatment of carcinoid tumors and large-cell neuroendocrine cancer of the lung.Cancers (Basel). 2022; 14: 177
- Capecitabine and temozolomide in advanced lung neuroendocrine neoplasms.Oncologist. 2020; 25: e48-e52
- Capecitabine and temozolomide in patients with advanced pulmonary carcinoid tumours.Neuroendocrinology. 2020; 110: 413-421
- Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).Lung Cancer. 2020; 150: 70-75
- Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement.Oncologist. 2016; 21: 1191
- Peptide receptor radionuclide therapy outcomes in a north american cohort with metastatic well-differentiated neuroendocrine tumors.Pancreas. 2017; 46: 151-156
- The role of surgery in high-grade neuroendocrine cancer: indications for clinical practice.Front Med. 2022; 9: 869320
- Neuroendocrine carcinomas of the digestive tract: what is new?.Cancers (Basel). 2021; 13
- Carboplatin in combination with oral or intravenous etoposide for extra-pulmonary, poorly-differentiated neuroendocrine carcinomas.Neuroendocrinology. 2019; 109: 100-112
- The north american neuroendocrine society (NANETS) consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors.Pancreas. 2017; 46: 707
- A phase II basket trial of dual anti-CTLA-4 and Anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors.Clin Cancer Res. 2020; 26: 2290-2296
- A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: high-grade neuroendocrine neoplasm cohort.Cancer. 2021; 127: 3194-3201
- A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.Mod Pathol. 2018; 31: 1770
Article info
Publication history
Published online: January 25, 2023
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
